Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1994 Feb;219(2):183–192. doi: 10.1097/00000658-199402000-00010

Are events after endotoxemia related to circulating phospholipase A2?

A A Santos 1, J L Browning 1, M R Scheltinga 1, E A Lynch 1, E F Brown 1, P Lawton 1, E Chambers 1, I Dougas 1, C D Benjamin 1, C A Dinarello 1, et al.
PMCID: PMC1243120  PMID: 8129489

Abstract

OBJECTIVE: The authors sought to determine whether the signs and symptoms of endotoxemia were related to the endotoxin-stimulated increase in circulating phospholipase A2 (PLA2) activity. BACKGROUND: Because hypotension and pulmonary injury have been associated with elevated PLA2 activity in septic shock and PLA2 levels are reduced with the administration of glucocorticoids, the PLA2 response to endotoxin was investigated in volunteers pretreated with and without hydrocortisone. METHODS: Carefully screened human subjects were studied under four conditions: (1) saline, (2) hydrocortisone, (3) endotoxin, and (4) hydrocortisone administration before endotoxin exposure. Pulse rate, blood pressure, temperature, and symptoms of endotoxemia were serially measured. Plasma for tumor necrosis factor concentrations and PLA2 activity was obtained. RESULTS: After lipopolysaccharide, pulse rate and tumor necrosis factor concentrations rose at 1 to 2 hours; temperature increased maximally at 4 hours. PLA2 activity reached peak levels at 24 hours. With hydrocortisone pretreatment, a 50% reduction in the concentrations of tumor necrosis factor and PLA2 occurred. Significant correlations between other variables and PLA2 activity were not observed. The enzyme identified by monoclonal antibody was the secreted nonpancreatic PLA2 (SNP-PLA2). CONCLUSIONS: The results of this study suggest that elevations in circulating SNP-PLA2 activity and systemic events associated with intravenous endotoxin administration are unrelated.

Full text

PDF
183

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barber A. E., Coyle S. M., Marano M. A., Fischer E., Calvano S. E., Fong Y., Moldawer L. L., Lowry S. F. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol. 1993 Mar 1;150(5):1999–2006. [PubMed] [Google Scholar]
  2. Bomalaski J. S., Lawton P., Browning J. L. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Immunol. 1991 Jun 1;146(11):3904–3910. [PubMed] [Google Scholar]
  3. Bone R. C., Fisher C. J., Jr, Clemmer T. P., Slotman G. J., Metz C. A., Balk R. A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987 Sep 10;317(11):653–658. doi: 10.1056/NEJM198709103171101. [DOI] [PubMed] [Google Scholar]
  4. Chang J., Musser J. H., McGregor H. Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol. 1987 Aug 1;36(15):2429–2436. doi: 10.1016/0006-2952(87)90512-0. [DOI] [PubMed] [Google Scholar]
  5. Crowl R. M., Stoller T. J., Conroy R. R., Stoner C. R. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991 Feb 5;266(4):2647–2651. [PubMed] [Google Scholar]
  6. Demling R. H., Smith M., Gunther R., Flynn J. T., Gee M. H. Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. Am J Physiol. 1981 Mar;240(3):H348–H353. doi: 10.1152/ajpheart.1981.240.3.H348. [DOI] [PubMed] [Google Scholar]
  7. Dennis E. A., Rhee S. G., Billah M. M., Hannun Y. A. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J. 1991 Apr;5(7):2068–2077. doi: 10.1096/fasebj.5.7.1901288. [DOI] [PubMed] [Google Scholar]
  8. Flower R. J. Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol. 1988 Aug;94(4):987–1015. doi: 10.1111/j.1476-5381.1988.tb11614.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. GREISMAN S. E., HORNICK R. B., CAROZZA F. A., Jr, WOODWARD T. E. The role of endotoxin during typhoid fever and tularemia in man. I. Acquisition of tolerance to endotoxin. J Clin Invest. 1963 Jul;42:1064–1075. doi: 10.1172/JCI104792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goppelt-Struebe M., Rehfeldt W. Glucocorticoids inhibit TNF alpha-induced cytosolic phospholipase A2 activity. Biochim Biophys Acta. 1992 Jul 29;1127(2):163–167. doi: 10.1016/0005-2760(92)90273-x. [DOI] [PubMed] [Google Scholar]
  11. Green J. A., Smith G. M., Buchta R., Lee R., Ho K. Y., Rajkovic I. A., Scott K. F. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation. 1991 Oct;15(5):355–367. doi: 10.1007/BF00917352. [DOI] [PubMed] [Google Scholar]
  12. Greisman S. E., Hornick R. B. Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med. 1969 Sep;131(4):1154–1158. doi: 10.3181/00379727-131-34059. [DOI] [PubMed] [Google Scholar]
  13. Heath M. F., Tighe D., Moss R., Bennett E. D. Relevance of serum phospholipase A2 assays to the assessment of septic shock. Crit Care Med. 1990 Jul;18(7):766–767. doi: 10.1097/00003246-199007000-00018. [DOI] [PubMed] [Google Scholar]
  14. Hesse D. G., Tracey K. J., Fong Y., Manogue K. R., Palladino M. A., Jr, Cerami A., Shires G. T., Lowry S. F. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988 Feb;166(2):147–153. [PubMed] [Google Scholar]
  15. Hochstein H. D., Mills D. F., Outschoorn A. S., Rastogi S. C. The processing and collaborative assay of a reference endotoxin. J Biol Stand. 1983 Oct;11(4):251–260. doi: 10.1016/s0092-1157(83)80013-4. [DOI] [PubMed] [Google Scholar]
  16. Hoffmann G. E., Schmidt D., Bastian B., Guder W. G. Photometric determination of phospholipase A. J Clin Chem Clin Biochem. 1986 Nov;24(11):871–875. doi: 10.1515/cclm.1986.24.11.871. [DOI] [PubMed] [Google Scholar]
  17. Lin L. L., Lin A. Y., DeWitt D. L. Interleukin-1 alpha induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. J Biol Chem. 1992 Nov 25;267(33):23451–23454. [PubMed] [Google Scholar]
  18. Mansbach C. M., 2nd Phospholipases: old enzymes with new meaning. Gastroenterology. 1990 May;98(5 Pt 1):1369–1382. doi: 10.1016/0016-5085(90)90359-9. [DOI] [PubMed] [Google Scholar]
  19. Martich G. D., Danner R. L., Ceska M., Suffredini A. F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 1991 Apr 1;173(4):1021–1024. doi: 10.1084/jem.173.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  21. Michie H. R., Wilmore D. W. Sepsis, signals, and surgical sequelae (a hypothesis). Arch Surg. 1990 Apr;125(4):531–536. doi: 10.1001/archsurg.1990.01410160119023. [DOI] [PubMed] [Google Scholar]
  22. Murakami M., Kudo I., Natori Y., Inoue K. Immunochemical detection of 'platelet type' phospholipase A2 in the rat. Biochim Biophys Acta. 1990 Mar 12;1043(1):34–42. doi: 10.1016/0005-2760(90)90107-9. [DOI] [PubMed] [Google Scholar]
  23. Nakano T., Arita H. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 1990 Oct 29;273(1-2):23–26. doi: 10.1016/0014-5793(90)81042-m. [DOI] [PubMed] [Google Scholar]
  24. Nakano T., Ohara O., Teraoka H., Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem. 1990 Jul 25;265(21):12745–12748. [PubMed] [Google Scholar]
  25. Nieuwenhuizen W., Kunze H., de Haas G. H. Phospholipase A2 (phosphatide acylhydrolase, EC 3.1.1.4) from porcine pancreas. Methods Enzymol. 1974;32:147–154. doi: 10.1016/0076-6879(74)32018-6. [DOI] [PubMed] [Google Scholar]
  26. Pruzanski W., Vadas P. Phospholipase A2--a mediator between proximal and distal effectors of inflammation. Immunol Today. 1991 May;12(5):143–146. doi: 10.1016/S0167-5699(05)80042-8. [DOI] [PubMed] [Google Scholar]
  27. Pruzanski W., Wilmore D. W., Suffredini A., Martich G. D., Hoffman A. G., Browning J. L., Stefanski E., Sternby B., Vadas P. Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin. Inflammation. 1992 Oct;16(5):561–570. doi: 10.1007/BF00918980. [DOI] [PubMed] [Google Scholar]
  28. Revhaug A., Michie H. R., Manson J. M., Watters J. M., Dinarello C. A., Wolff S. M., Wilmore D. W. Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg. 1988 Feb;123(2):162–170. doi: 10.1001/archsurg.1988.01400260042004. [DOI] [PubMed] [Google Scholar]
  29. Santos A. A., Scheltinga M. R., Lynch E., Brown E. F., Lawton P., Chambers E., Browning J., Dinarello C. A., Wolff S. M., Wilmore D. W. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg. 1993 Feb;128(2):138–144. doi: 10.1001/archsurg.1993.01420140015003. [DOI] [PubMed] [Google Scholar]
  30. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976 Sep;184(3):333–341. doi: 10.1097/00000658-197609000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sigel M. B., Sinha Y. N., VanderLaan W. P. Production of antibodies by inoculation into lymph nodes. Methods Enzymol. 1983;93:3–12. doi: 10.1016/s0076-6879(83)93031-8. [DOI] [PubMed] [Google Scholar]
  32. Spinas G. A., Bloesch D., Kaufmann M. T., Keller U., Dayer J. M. Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol. 1990 Nov;259(5 Pt 2):R993–R997. doi: 10.1152/ajpregu.1990.259.5.R993. [DOI] [PubMed] [Google Scholar]
  33. Sprung C. L., Caralis P. V., Marcial E. H., Pierce M., Gelbard M. A., Long W. M., Duncan R. C., Tendler M. D., Karpf M. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984 Nov 1;311(18):1137–1143. doi: 10.1056/NEJM198411013111801. [DOI] [PubMed] [Google Scholar]
  34. Stoner C. R., Reik L. M., Donohue M., Levin W., Crowl R. M. Human group II phospholipase A2. Characterization of monoclonal antibodies and immunochemical quantitation of the protein in synovial fluid. J Immunol Methods. 1991 Dec 15;145(1-2):127–136. doi: 10.1016/0022-1759(91)90318-a. [DOI] [PubMed] [Google Scholar]
  35. Suffredini A. F., Fromm R. E., Parker M. M., Brenner M., Kovacs J. A., Wesley R. A., Parrillo J. E. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989 Aug 3;321(5):280–287. doi: 10.1056/NEJM198908033210503. [DOI] [PubMed] [Google Scholar]
  36. Suwa Y., Kudo I., Imaizumi A., Okada M., Kamimura T., Suzuki Y., Chang H. W., Hara S., Inoue K. Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in rats. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2395–2399. doi: 10.1073/pnas.87.7.2395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sánchez Crespo M., Fernández-Gallardo S. Pharmacological modulation of PAF: a therapeutic approach to endotoxin shock. J Lipid Mediat. 1991 Sep-Oct;4(2):127–143. [PubMed] [Google Scholar]
  38. Vadas P., Browning J., Edelson J., Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat. 1993 Aug;8(1):1–30. [PubMed] [Google Scholar]
  39. Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med. 1984 Dec;104(6):873–881. [PubMed] [Google Scholar]
  40. Vadas P., Hay J. B. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol. 1983 Jun;61(6):561–566. doi: 10.1139/y83-086. [DOI] [PubMed] [Google Scholar]
  41. Vadas P., Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock. 1993 Feb;39(2):160–167. [PubMed] [Google Scholar]
  42. Vadas P., Pruzanski W. Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest. 1986 Oct;55(4):391–404. [PubMed] [Google Scholar]
  43. Vadas P., Pruzanski W., Stefanski E., Sternby B., Mustard R., Bohnen J., Fraser I., Farewell V., Bombardier C. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med. 1988 Jan;16(1):1–7. doi: 10.1097/00003246-198801000-00001. [DOI] [PubMed] [Google Scholar]
  44. Veterans Administration Systemic Sepsis Cooperative Study Group Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987 Sep 10;317(11):659–665. doi: 10.1056/NEJM198709103171102. [DOI] [PubMed] [Google Scholar]
  45. Zuckerman S. H., Bendele A. M. Regulation of serum tumor necrosis factor in glucocorticoid-sensitive and -resistant rodent endotoxin shock models. Infect Immun. 1989 Oct;57(10):3009–3013. doi: 10.1128/iai.57.10.3009-3013.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. van der Meer J. W., Endres S., Lonnemann G., Cannon J. G., Ikejima T., Okusawa S., Gelfand J. A., Dinarello C. A. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukoc Biol. 1988 Mar;43(3):216–223. doi: 10.1002/jlb.43.3.216. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES